Report Summary
Summary
Solid tumors are an abnormal mass of tissue that do not contain cysts or liquid areas. These may be malignant (cancerous) or benign (not cancerous). They affect bones, organs, and muscles. Based on the type of the cells, solid tumors can be carcinomas, sarcomas, and lymphomas.
During 2017, the biologics segment dominated the market and accounted for close to 55% of the market share in terms of revenue. This segment consists of medicinal products extracted from biological sources such as human, animal, microorganisms, or they are manufactured using the latest, cutting-edge biotechnological processes. Biologics include products such as enzymes, blood and blood components, gene therapy, recombinant proteins, somatic cells, tissues, and vaccines.
In terms of geography, the Americas dominated the global solid tumors drugs market. The growth of this market in the Americas is attributed to the increasing uptake of existing biologics drugs and the launch of new biologics. However, the revenue from these drugs will decrease during the forecast period because of the loss of patent exclusivity of drugs, leading to the entry of generics. This decline is expected to be partially offset by favorable reimbursement plans by the government, such as the provision of Medicare and Medicaid. The US is the largest revenue contributor in this region.
In 2020, the global Solid Tumors Drugs market size was xx million US$ and it is expected to reach xx million US$ by the end of 2027, with a CAGR of xx% between 2021 and 2027.
This report studies the Solid Tumors Drugs market size by players, regions, product types and end industries, history data 2017-2020 and forecast data 2021-2027; This report also studies the global market competition landscape, market drivers and trends, opportunities and challenges, risks and entry barriers, sales channels, distributors and Porter's Five Forces Analysis.
This report focuses on the global top players, covered
Hoffmann-La Roche
Novartis
Celgene
Johnson & Johnson
Pfizer
BMS
Eli Lilly
GSK
Merck
Sanofi
AbbVie
AstraZeneca
Bayer
Biogen
Boehringer Ingelheim
Boston Biomedical
Daiichi Sankyo
Market segment by Regions/Countries, this report covers
North America
Europe
China
Rest of Asia Pacific
Central & South America
Middle East & Africa
Market segment by Type, the product can be split into
Small Molecules
Biologics
Market segment by Application, the market can be split into
Hospitals
Clinics
Academic and Research Institutes
The study objectives of this report are:
To study and forecast the market size of Solid Tumors Drugs in global market.
To analyze the global key players, SWOT analysis, value and global market share for top players.
To define, describe and forecast the market by type, end use and region.
To analyze and compare the market status and forecast among global major regions.
To analyze the global key regions market potential and advantage, opportunity and challenge, restraints and risks.
To identify significant trends and factors driving or inhibiting the market growth.
To analyze the opportunities in the market for stakeholders by identifying the high growth segments.
To strategically analyze each submarket with respect to individual growth trend and their contribution to the market
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
To strategically profile the key players and comprehensively analyze their growth strategies.
In this study, the years considered to estimate the market size of Solid Tumors Drugs are as follows:
History Year: 2017-2020
Base Year: 2020
Estimated Year: 2020
Forecast Year 2021 to 2027
For the data information by region, company, type and application, 2020 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
Key Stakeholders
Raw material suppliers
Distributors/traders/wholesalers/suppliers
Regulatory bodies, including government agencies and NGO
Commercial research & development (R&D) institutions
Importers and exporters
Government organizations, research organizations, and consulting firms
Trade associations and industry bodies
End-use industries
Available Customizations
With the given market data, EternityInsights offers customizations according to the company's specific needs. The following customization options are available for the report:
Further breakdown of Solid Tumors Drugs market on basis of the key contributing countries.
Detailed analysis and profiling of additional market players.
Table Of Contents
Table of Contents
Solid Tumors Drugs Market Report by Company, Regions, Types and Applications, Global Status and Forecast to 2025
1 Industry Overview of Solid Tumors Drugs
1.1 Solid Tumors Drugs Market Overview
1.1.1 Solid Tumors Drugs Product Scope
1.1.2 Market Status and Outlook
1.2 Global Solid Tumors Drugs Market Size and Analysis by Regions
1.2.1 North America
1.2.2 Europe
1.2.3 China
1.2.4 Rest of Asia Pacific
1.2.5 Central & South America
1.2.6 Middle East & Africa
1.3 Solid Tumors Drugs Market by Type
1.3.1 Small Molecules
1.3.2 Biologics
1.4 Solid Tumors Drugs Market by End Users/Application
1.4.1 Hospitals
1.4.2 Clinics
1.4.3 Academic and Research Institutes
2 Global Solid Tumors Drugs Competition Analysis by Players
2.1 Solid Tumors Drugs Market Size (Value) by Players (2019 and 2020)
2.2 Competitive Status and Trend
2.2.1 Market Concentration Rate
2.2.2 Product/Service Differences
2.2.3 New Entrants
2.2.4 The Technology Trends in Future
3 Company (Top Players) Profiles
3.1 Hoffmann-La Roche
3.1.1 Company Profile
3.1.2 Main Business/Business Overview
3.1.3 Products, Services and Solutions
3.1.4 Solid Tumors Drugs Revenue (Value) (2017-2020)
3.1.5 Recent Developments
3.2 Novartis
3.2.1 Company Profile
3.2.2 Main Business/Business Overview
3.2.3 Products, Services and Solutions
3.2.4 Solid Tumors Drugs Revenue (Value) (2017-2020)
3.2.5 Recent Developments
3.3 Celgene
3.3.1 Company Profile
3.3.2 Main Business/Business Overview
3.3.3 Products, Services and Solutions
3.3.4 Solid Tumors Drugs Revenue (Value) (2017-2020)
3.3.5 Recent Developments
3.4 Johnson & Johnson
3.4.1 Company Profile
3.4.2 Main Business/Business Overview
3.4.3 Products, Services and Solutions
3.4.4 Solid Tumors Drugs Revenue (Value) (2017-2020)
3.4.5 Recent Developments
3.5 Pfizer
3.5.1 Company Profile
3.5.2 Main Business/Business Overview
3.5.3 Products, Services and Solutions
3.5.4 Solid Tumors Drugs Revenue (Value) (2017-2020)
3.5.5 Recent Developments
3.6 BMS
3.6.1 Company Profile
3.6.2 Main Business/Business Overview
3.6.3 Products, Services and Solutions
3.6.4 Solid Tumors Drugs Revenue (Value) (2017-2020)
3.6.5 Recent Developments
3.7 Eli Lilly
3.7.1 Company Profile
3.7.2 Main Business/Business Overview
3.7.3 Products, Services and Solutions
3.7.4 Solid Tumors Drugs Revenue (Value) (2017-2020)
3.7.5 Recent Developments
3.8 GSK
3.8.1 Company Profile
3.8.2 Main Business/Business Overview
3.8.3 Products, Services and Solutions
3.8.4 Solid Tumors Drugs Revenue (Value) (2017-2020)
3.8.5 Recent Developments
3.9 Merck
3.9.1 Company Profile
3.9.2 Main Business/Business Overview
3.9.3 Products, Services and Solutions
3.9.4 Solid Tumors Drugs Revenue (Value) (2017-2020)
3.9.5 Recent Developments
3.10 Sanofi
3.10.1 Company Profile
3.10.2 Main Business/Business Overview
3.10.3 Products, Services and Solutions
3.10.4 Solid Tumors Drugs Revenue (Value) (2017-2020)
3.10.5 Recent Developments
3.11 AbbVie
3.12 AstraZeneca
3.13 Bayer
3.14 Biogen
3.15 Boehringer Ingelheim
3.16 Boston Biomedical
3.17 Daiichi Sankyo
4 Global Solid Tumors Drugs Market Size by Type and Application (2017-2020)
4.1 Global Solid Tumors Drugs Market Size by Type (2017-2020)
4.2 Global Solid Tumors Drugs Market Size by Application (2017-2020)
4.3 Potential Application of Solid Tumors Drugs in Future
4.4 Top Consumer/End Users of Solid Tumors Drugs
5 North America Solid Tumors Drugs Development Status and Outlook
5.1 North America Solid Tumors Drugs Market Size (2017-2020)
5.2 North America Solid Tumors Drugs Market Size and Market Share by Players (2019 and 2020)
6 Europe Solid Tumors Drugs Development Status and Outlook
6.1 Europe Solid Tumors Drugs Market Size (2017-2020)
6.2 Europe Solid Tumors Drugs Market Size and Market Share by Players (2019 and 2020)
7 China Solid Tumors Drugs Development Status and Outlook
7.1 China Solid Tumors Drugs Market Size (2017-2020)
7.2 China Solid Tumors Drugs Market Size and Market Share by Players (2019 and 2020)
8 Rest of Asia Pacific Solid Tumors Drugs Development Status and Outlook
8.1 Rest of Asia Pacific Solid Tumors Drugs Market Size (2017-2020)
8.2 Rest of Asia Pacific Solid Tumors Drugs Market Size and Market Share by Players (2019 and 2020)
9 Central & South America Solid Tumors Drugs Development Status and Outlook
9.1 Central & South America Solid Tumors Drugs Market Size (2017-2020)
9.2 Central & South America Solid Tumors Drugs Market Size and Market Share by Players (2019 and 2020)
10 Middle East & Africa Solid Tumors Drugs Development Status and Outlook
10.1 Middle East & Africa Solid Tumors Drugs Market Size (2017-2020)
10.2 Middle East & Africa Solid Tumors Drugs Market Size and Market Share by Players (2019 and 2020)
11 Market Forecast by Regions, Type and Application (2021-2027)
11.1 Global Solid Tumors Drugs Market Size (Value) by Regions (2021-2027)
11.1.1 North America Solid Tumors Drugs Revenue and Growth Rate (2021-2027)
11.1.2 Europe Solid Tumors Drugs Revenue and Growth Rate (2021-2027)
11.1.3 China Solid Tumors Drugs Revenue and Growth Rate (2021-2027)
11.1.4 Rest of Asia Pacific Solid Tumors Drugs Revenue and Growth Rate (2021-2027)
11.1.5 Central & South America Solid Tumors Drugs Revenue and Growth Rate (2021-2027)
11.1.6 Middle East & Africa Solid Tumors Drugs Revenue and Growth Rate (2021-2027)
11.2 Global Solid Tumors Drugs Market Size (Value) by Type (2021-2027)
11.3 Global Solid Tumors Drugs Market Size by Application (2021-2027)
12 Solid Tumors Drugs Market Dynamics
12.1 Solid Tumors Drugs Market Opportunities
12.2 Solid Tumors Drugs Challenge and Risk
12.2.1 Competition from Opponents
12.2.2 Downside Risks of Economy
12.3 Solid Tumors Drugs Market Constraints and Threat
12.3.1 Threat from Substitute
12.3.2 Government Policy
12.3.3 Technology Risks
12.4 Solid Tumors Drugs Market Driving Force
12.4.1 Growing Demand from Emerging Markets
12.4.2 Potential Application
13 Market Effect Factors Analysis
13.1 Technology Progress/Risk
13.1.1 Substitutes
13.1.2 Technology Progress in Related Industry
13.2 Consumer Needs Trend/Customer Preference
13.3 External Environmental Change
13.3.1 Economic Fluctuations
13.3.2 Other Risk Factors
14 Research Finding/Conclusion
15 Appendix
Methodology
Analyst Introduction
Data Source
